This page shows the latest Antibody cocktail news and features for those working in and with pharma, biotech and healthcare.
Another COVID-19 antibody cocktail, developed by Regeneron, also holds an EUA in the US for the treatment of mild-to-moderate high-risk COVID-19 patients. ... As part of the US’ Operation Warp Speed initiative, Regeneron signed an agreement for the
A COVID-19 antibody cocktail developed by Regeneron has been given an emergency use authorisation (EUA) from the US Food and Drug Administration (FDA). ... As part of that agreement, Regeneron was awarded a $450m contract by the government bodies to
Another drugmaker, Regeneron, is also looking to obtain an EUA from the FDA for its COVID-19 antibody cocktail, REGN-COV2. ... Medical visits were reduced by 72% in patients with one or more risk factors who were receiving the investigational antibody
Trial modified based on recommendations from independent data monitoring committee. Regeneron has announced that it has stopped enrolment of severely ill COVID-19 patients into its antibody cocktail treatment trials based ... According to Regeneron, the
In August, Roche also partnered with Regeneron to bolster manufacturing and global development capabilities for the latter’s investigational antibody cocktail for COVID-19.
A number of companies are developing antibodies for COVID-19, with the most notable probably being Regeneron’s antibody cocktail REGN-COV2.
More from news
Approximately 1 fully matching, plus 14 partially matching documents found.
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...